Either a recombinant version does not yet exist as a therapeutic agent or the recombinant version so far fails to meet therapeutic requirements.

Our first CAP® cell derived molecule entering a clinical Phase I trial has been codeveloped with Alloksys Life Science BV (Netherlands), highlighting the successful regulatory approval of CAP®-Technology. Promising additional candidate molecules are in later preclinical development and ready to follow.